Skip to content

Precigen PGEN Cumulative Gross Losses and Impairments

Cumulative Gross Losses and Impairments at other companies

Merck & Co. logo
Merck & Co.MRK
$531M0.0%

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.93B+213%

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:GoodwillImpairedAccumulatedImpairmentLoss.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's cumulative gross losses and impairments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's cumulative gross losses and impairments?
Precigen (PGEN) reported cumulative gross losses and impairments of $36.19M in Q1 2026.
How has Precigen's cumulative gross losses and impairments changed year-over-year?
Precigen's cumulative gross losses and impairments increased by 12.1% year-over-year, from $32.28M to $36.19M.
What is the long-term trend for Precigen's cumulative gross losses and impairments?
Over 5 years (2020 to 2025), Precigen's cumulative gross losses and impairments has grown at a -3.7% compound annual growth rate (CAGR), from $43.64M to $36.19M.
What does cumulative gross losses and impairments mean?
This metric aggregates all unrealized losses and recognized impairment charges on investment securities that have not yet been realized through a sale. It provides a comprehensive view of the negative valuation adjustments impacting the bank's equity. It is a key indicator of the credit and market risk embedded in the bank's long-term holdings.